{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:55:24Z","timestamp":1788479724217,"version":"build-2803163510"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:00:00Z","timestamp":1632528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:00:00Z","timestamp":1632528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["843002806"],"award-info":[{"award-number":["843002806"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>First-line treatment for prolactinomas is a medical treatment with dopamine agonists (DAs), which effectively control hyperprolactinaemia in most patients, although post-withdrawal remission rates are approximately 34%. Therefore, many patients require prolonged DA treatment, while side effects negatively impact health-related quality of life (HRQoL). Endoscopic transsphenoidal resection is reserved for patients with severe side effects, or with DA-resistant prolactinoma. Surgery has a good safety profile and high probability of remission and may thus deserve a more prominent place in prolactinoma treatment. The hypothesis for this study is that early or upfront surgical resection is superior to DA treatment both in terms of HRQoL and remission rate in patients with a non-invasive prolactinoma of limited size.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We present a combined randomised clinical trial and observational cohort study design, which comprises three unblinded randomised controlled trials (RCTs; PRolaCT-1, PRolaCT-2, PRolaCT-3), and an observational study arm (PRolaCT-O) that compare neurosurgical counselling, and potential subsequent endoscopic transsphenoidal adenoma resection, with current standard care. Patients with a non-invasive prolactinoma (&lt; 25 mm) will be eligible for one of three RCTs based on the duration of pre-treatment with DAs: PRolaCT-1: newly diagnosed, treatment-na\u00efve patients; PRolaCT-2: patients with limited duration of DA treatment (4\u20136 months); and PRolaCT-3: patients with persisting prolactinoma after DA treatment for &gt; 2 years. PRolaCT-O will include patients who decline randomisation, due to e.g. a clear treatment preference. Primary outcomes are disease remission after 36 months and HRQoL after 12 months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>Early or upfront surgical resection for patients with a limited-sized prolactinoma may be a reasonable alternative to the current standard practice of DA treatment, which we will investigate in three RCTs and an observational cohort study. Within the three RCTs, patients will be randomised between neurosurgical counselling and standard care. The observational study arm will recruit patients who refuse randomisation and have a pronounced treatment preference. PRolaCT will collect randomised and observational data, which may facilitate a more individually tailored practice of evidence-based medicine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>US National Library of Medicine registry (ClinicalTrials.gov) <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04107480\">NCT04107480<\/jats:ext-link>. Registered on 27 September 2019, registered retrospectively (by 2 months).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-021-05604-y","type":"journal-article","created":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T19:02:53Z","timestamp":1632596573000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The PRolaCT studies \u2014\u00a0a study protocol for a combined randomised clinical trial and observational cohort study design in prolactinoma"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1077-8273","authenticated-orcid":false,"given":"Ingrid M.","family":"Zandbergen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir H.","family":"Zamanipoor Najafabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris C. M.","family":"Pelsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Elske","family":"van den Akker-van Marle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter H. L. T.","family":"Bisschop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. D. Jeroen","family":"Boogaarts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianne C.","family":"van Bon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bakhtyar","family":"Burhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"le Cessie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf M.","family":"Dekkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine L.","family":"Drent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Feelders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan P.","family":"de Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hoogmoed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kitty K.","family":"Kapiteijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie M.","family":"van der Klauw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willy-Anne C. M.","family":"Nieuwlaat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto M.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline M. E.","family":"Stades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annenienke C.","family":"van de Ven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris M. M. J.","family":"Wakelkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter R.","family":"van Furth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nienke R.","family":"Biermasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Dutch Prolactinoma Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,25]]},"reference":[{"issue":"5","key":"5604_CR1","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jama.2016.19699","volume":"317","author":"ME Molitch","year":"2017","unstructured":"Molitch ME. Diagnosis and treatment of pituitary adenomas: a review. Jama. 2017;317(5):516\u201324. https:\/\/doi.org\/10.1001\/jama.2016.19699.","journal-title":"Jama."},{"issue":"4","key":"5604_CR2","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s11102-012-0454-0","volume":"16","author":"M Gruppetta","year":"2013","unstructured":"Gruppetta M, Mercieca C, Vassallo J. Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary. 2013;16(4):545\u201353. https:\/\/doi.org\/10.1007\/s11102-012-0454-0.","journal-title":"Pituitary."},{"issue":"8","key":"5604_CR3","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1210\/jc.2009-0177","volume":"94","author":"M Kars","year":"2009","unstructured":"Kars M, Souverein PC, Herings RM, Romijn JA, Vandenbroucke JP, de Boer A, et al. Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. J Clin Endocrinol Metab. 2009;94(8):2729\u201334. https:\/\/doi.org\/10.1210\/jc.2009-0177.","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"5604_CR4","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273\u201388. https:\/\/doi.org\/10.1210\/jc.2010-1692.","journal-title":"J Clin Endocrinol Metab."},{"key":"5604_CR5","doi-asserted-by":"publisher","unstructured":"Zamanipoor Najafabadi AH, Zandbergen IM, de Vries F, LHA B, van den Akker-van Marle ME, Pereira AM, et al. Surgery as a viable alternative first-line treatment for prolactinoma patients. A systematic review and meta-analysis. J Clin Endocrinol Metab. 2020;105(3):e32\u201341. https:\/\/doi.org\/10.1210\/clinem\/dgz144.","DOI":"10.1210\/clinem\/dgz144"},{"issue":"1","key":"5604_CR6","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11102-014-0561-1","volume":"18","author":"CD Andela","year":"2015","unstructured":"Andela CD, Niemeijer ND, Scharloo M, Tiemensma J, Kanagasabapathy S, Pereira AM, et al. Towards a better quality of life (QoL) for patients with pituitary diseases: results from a focus group study exploring QoL. Pituitary. 2015;18(1):86\u2013100. https:\/\/doi.org\/10.1007\/s11102-014-0561-1.","journal-title":"Pituitary."},{"issue":"1","key":"5604_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1530\/EJE-12-0121","volume":"167","author":"A Elenkova","year":"2012","unstructured":"Elenkova A, Shabani R, Kalinov K, Zacharieva S. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment. Eur J Endocrinol. 2012;167(1):17\u201325. https:\/\/doi.org\/10.1530\/EJE-12-0121.","journal-title":"Eur J Endocrinol."},{"issue":"6","key":"5604_CR8","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1530\/acta.0.1260489","volume":"126","author":"C Ferrari","year":"1992","unstructured":"Ferrari C, Paracchi A, Mattei AM, de Vincentiis S, D'Alberton A, Crosignani P. Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol. 1992;126(6):489\u201394. https:\/\/doi.org\/10.1530\/acta.0.1260489.","journal-title":"Acta Endocrinol."},{"issue":"3-4","key":"5604_CR9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/0753-3322(94)90105-8","volume":"48","author":"B Merola","year":"1994","unstructured":"Merola B, Sarnacchiaro F, Colao A, Di Somma C, Di Sarno A, Landi ML, et al. CV 205-502 in the treatment of tumoral and non-tumoral hyperprolactinemic states. Biomed Pharmacother. 1994;48(3-4):167\u201374.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"5604_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11102-008-0134-2","volume":"12","author":"S Vallette","year":"2009","unstructured":"Vallette S, Serri K, Rivera J, Santagata P, Delorme S, Garfield N, et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary. 2009;12(3):153\u20137. https:\/\/doi.org\/10.1007\/s11102-008-0134-2.","journal-title":"Pituitary."},{"issue":"3","key":"5604_CR11","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2265.1993.tb02372.x","volume":"39","author":"J Webster","year":"1993","unstructured":"Webster J, Piscitelli G, Polli A, D'Alberton A, Falsetti L, Ferrari C, et al. The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. European Multicentre Cabergoline Study Group. Clin Endocrinol. 1993;39(3):323\u20139. https:\/\/doi.org\/10.1111\/j.1365-2265.1993.tb02372.x.","journal-title":"Clin Endocrinol."},{"issue":"14","key":"5604_CR12","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1056\/NEJM199410063311403","volume":"331","author":"J Webster","year":"1994","unstructured":"Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. New Engl J Med. 1994;331(14):904\u20139. https:\/\/doi.org\/10.1056\/NEJM199410063311403.","journal-title":"New Engl J Med."},{"issue":"2","key":"5604_CR13","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1007\/s12020-016-1088-1","volume":"55","author":"SM De Sousa","year":"2017","unstructured":"De Sousa SM, Chapman IM, Falhammar H, Torpy DJ. Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists. Endocrine. 2017;55(2):618\u201324. https:\/\/doi.org\/10.1007\/s12020-016-1088-1.","journal-title":"Endocrine."},{"issue":"6","key":"5604_CR14","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/cen.12375","volume":"80","author":"I Bancos","year":"2014","unstructured":"Bancos I, Nannenga MR, Bostwick JM, Silber MH, Erickson D, Nippoldt TB. Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study. Clin Endocrinol. 2014;80(6):863\u20138. https:\/\/doi.org\/10.1111\/cen.12375.","journal-title":"Clin Endocrinol."},{"issue":"2","key":"5604_CR15","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s11102-013-0480-6","volume":"17","author":"M Barake","year":"2014","unstructured":"Barake M, Evins AE, Stoeckel L, Pachas GN, Nachtigall LB, Miller KK, et al. Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study. Pituitary. 2014;17(2):150\u20136. https:\/\/doi.org\/10.1007\/s11102-013-0480-6.","journal-title":"Pituitary."},{"issue":"12","key":"5604_CR16","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1001\/jamainternmed.2014.5262","volume":"174","author":"TJ Moore","year":"2014","unstructured":"Moore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med. 2014;174(12):1930\u20133. https:\/\/doi.org\/10.1001\/jamainternmed.2014.5262.","journal-title":"JAMA Intern Med."},{"issue":"3","key":"5604_CR17","doi-asserted-by":"publisher","first-page":"R89","DOI":"10.1530\/EJE-16-0087","volume":"175","author":"M Tampourlou","year":"2016","unstructured":"Tampourlou M, Trifanescu R, Paluzzi A, Ahmed SK, Karavitaki N. Therapy of endocrine disease: surgery in microprolactinomas: effectiveness and risks based on contemporary literature. Eur J Endocrinol. 2016;175(3):R89\u201396. https:\/\/doi.org\/10.1530\/EJE-16-0087.","journal-title":"Eur J Endocrinol."},{"issue":"3","key":"5604_CR18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s11102-008-0091-9","volume":"11","author":"E Cesar de Oliveira Naliato","year":"2008","unstructured":"Cesar de Oliveira Naliato E, Dutra Violante AH, Caldas D, Lamounier Filho A, Rezende Loureiro C, Fontes R, et al. Quality of life in women with microprolactinoma treated with dopamine agonists. Pituitary. 2008;11(3):247\u201354. https:\/\/doi.org\/10.1007\/s11102-008-0091-9.","journal-title":"Pituitary."},{"issue":"2","key":"5604_CR19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1023\/B:PITU.0000004798.27230.ed","volume":"6","author":"MD Johnson","year":"2003","unstructured":"Johnson MD, Woodburn CJ, Vance ML. Quality of life in patients with a pituitary adenoma. Pituitary. 2003;6(2):81\u20137. https:\/\/doi.org\/10.1023\/B:PITU.0000004798.27230.ed.","journal-title":"Pituitary."},{"issue":"2","key":"5604_CR20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1530\/EJE-07-0259","volume":"157","author":"M Kars","year":"2007","unstructured":"Kars M, van der Klaauw AA, Onstein CS, Pereira AM, Romijn JA. Quality of life is decreased in female patients treated for microprolactinoma. Eur J Endocrinol. 2007;157(2):133\u20139. https:\/\/doi.org\/10.1530\/EJE-07-0259.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"5604_CR21","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/cen.12550","volume":"82","author":"E Ritvonen","year":"2015","unstructured":"Ritvonen E, Karppinen A, Sintonen H, Vehkavaara S, Kivipelto L, Roine RP, et al. Normal long-term health-related quality of life can be achieved in patients with functional pituitary adenomas having surgery as primary treatment. Clin Endocrinol. 2015;82(3):412\u201321. https:\/\/doi.org\/10.1111\/cen.12550.","journal-title":"Clin Endocrinol."},{"issue":"5","key":"5604_CR22","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1007\/s11102-015-0636-7","volume":"18","author":"CD Andela","year":"2015","unstructured":"Andela CD, Scharloo M, Pereira AM, Kaptein AA, Biermasz NR. Quality of life (QoL) impairments in patients with a pituitary adenoma: a systematic review of QoL studies. Pituitary. 2015;18(5):752\u201376. https:\/\/doi.org\/10.1007\/s11102-015-0636-7.","journal-title":"Pituitary."},{"issue":"1","key":"5604_CR23","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ecl.2014.10.010","volume":"44","author":"RF Dallapiazza","year":"2015","unstructured":"Dallapiazza RF, Jane JA Jr. Outcomes of endoscopic transsphenoidal pituitary surgery. Endocrinol Metab Clin North Am. 2015;44(1):105\u201315. https:\/\/doi.org\/10.1016\/j.ecl.2014.10.010.","journal-title":"Endocrinol Metab Clin North Am."},{"issue":"2","key":"5604_CR24","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.clineuro.2008.09.010","volume":"111","author":"A Tabaee","year":"2009","unstructured":"Tabaee A, Anand VK, Barron Y, Hiltzik DH, Brown SM, Kacker A, et al. Predictors of short-term outcomes following endoscopic pituitary surgery. Clin Neurol Neurosurg. 2009;111(2):119\u201322. https:\/\/doi.org\/10.1016\/j.clineuro.2008.09.010.","journal-title":"Clin Neurol Neurosurg."},{"issue":"6","key":"5604_CR25","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1007\/s00464-014-3815-0","volume":"29","author":"F Wang","year":"2015","unstructured":"Wang F, Zhou T, Wei S, Meng X, Zhang J, Hou Y, et al. Endoscopic endonasal transsphenoidal surgery of 1,166 pituitary adenomas. Surg Endosc. 2015;29(6):1270\u201380. https:\/\/doi.org\/10.1007\/s00464-014-3815-0.","journal-title":"Surg Endosc."},{"issue":"4","key":"5604_CR26","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11102-013-0502-4","volume":"17","author":"A Paluzzi","year":"2014","unstructured":"Paluzzi A, Fernandez-Miranda JC, Tonya Stefko S, Challinor S, Snyderman CH, Gardner PA. Endoscopic endonasal approach for pituitary adenomas: a series of 555 patients. Pituitary. 2014;17(4):307\u201319. https:\/\/doi.org\/10.1007\/s11102-013-0502-4.","journal-title":"Pituitary."},{"issue":"5","key":"5604_CR27","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11102-017-0838-2","volume":"20","author":"FF Casanueva","year":"2017","unstructured":"Casanueva FF, Barkan AL, Buchfelder M, Klibanski A, Laws ER, Loeffler JS, et al. Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): a Pituitary Society statement. Pituitary. 2017;20(5):489\u201398. https:\/\/doi.org\/10.1007\/s11102-017-0838-2.","journal-title":"Pituitary."},{"issue":"5","key":"5604_CR28","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1227\/01.neu.0000325862.83961.12","volume":"62","author":"AR Dehdashti","year":"2008","unstructured":"Dehdashti AR, Ganna A, Karabatsou K, Gentili F. Pure endoscopic endonasal approach for pituitary adenomas: early surgical results in 200 patients and comparison with previous microsurgical series. Neurosurgery. 2008;62(5):1006\u201315; discussion 15-7. https:\/\/doi.org\/10.1227\/01.neu.0000325862.83961.12.","journal-title":"Neurosurgery."},{"key":"5604_CR29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.wneu.2015.10.090","volume":"87","author":"PR Jethwa","year":"2016","unstructured":"Jethwa PR, Patel TD, Hajart AF, Eloy JA, Couldwell WT, Liu JK. Cost-effectiveness analysis of microscopic and endoscopic transsphenoidal surgery versus medical therapy in the management of microprolactinoma in the United States. World Neurosurg. 2016;87:65\u201376. https:\/\/doi.org\/10.1016\/j.wneu.2015.10.090.","journal-title":"World Neurosurg."},{"issue":"2","key":"5604_CR30","first-page":"125","volume":"78","author":"CC Zygourakis","year":"2017","unstructured":"Zygourakis CC, Imber BS, Chen R, Han SJ, Blevins L, Molinaro A, et al. Cost-effectiveness analysis of surgical versus medical treatment of prolactinomas. J Neuro Surg B Skull Base. 2017;78(2):125\u201331.","journal-title":"J Neuro Surg B Skull Base."},{"issue":"11","key":"5604_CR31","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S0895-4356(98)00097-3","volume":"51","author":"NK Aaronson","year":"1998","unstructured":"Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R, et al. Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epidemiol. 1998;51(11):1055\u201368. https:\/\/doi.org\/10.1016\/S0895-4356(98)00097-3.","journal-title":"J Clin Epidemiol."},{"key":"5604_CR32","doi-asserted-by":"publisher","unstructured":"McHorney CA, Ware JE, Jr., Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31(3):247-263, DOI: https:\/\/doi.org\/10.1097\/00005650-199303000-00006.","DOI":"10.1097\/00005650-199303000-00006"},{"key":"5604_CR33","doi-asserted-by":"publisher","unstructured":"Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473-483, DOI: https:\/\/doi.org\/10.1097\/00005650-199206000-00002.","DOI":"10.1097\/00005650-199206000-00002"},{"key":"5604_CR34","unstructured":"Nederland Z. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg. 2016."},{"issue":"11","key":"5604_CR35","doi-asserted-by":"publisher","first-page":"e0187477","DOI":"10.1371\/journal.pone.0187477","volume":"12","author":"TA Kanters","year":"2017","unstructured":"Kanters TA, Bouwmans CAM, van der Linden N, Tan SS, Hakkaart-van RL. Update of the Dutch manual for costing studies in health care. PLoS One. 2017;12(11):e0187477. https:\/\/doi.org\/10.1371\/journal.pone.0187477.","journal-title":"PLoS One."},{"issue":"4","key":"5604_CR36","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jval.2016.01.003","volume":"19","author":"MM Versteegh","year":"2016","unstructured":"Versteegh MM, Vermeulen KM, Evers SMAA, de Wit GA, Prenger R, Stolk EA. Dutch Tariff for the five-level version of EQ-5D. Value Health. 2016;19(4):343\u201352. https:\/\/doi.org\/10.1016\/j.jval.2016.01.003.","journal-title":"Value Health."},{"issue":"12","key":"5604_CR37","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s40618-016-0483-z","volume":"39","author":"E Sala","year":"2016","unstructured":"Sala E, Bellaviti Buttoni P, Malchiodi E, Verrua E, Carosi G, Profka E, et al. Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas. J Endocrinol Invest. 2016;39(12):1377\u201382. https:\/\/doi.org\/10.1007\/s40618-016-0483-z.","journal-title":"J Endocrinol Invest."},{"issue":"5","key":"5604_CR38","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s00701-016-2762-z","volume":"158","author":"S Akin","year":"2016","unstructured":"Akin S, Isikay I, Soylemezoglu F, Yucel T, Gurlek A, Berker M. Reasons and results of endoscopic surgery for prolactinomas: 142 surgical cases. Acta Neurochir (Wien). 2016;158(5):933\u201342. https:\/\/doi.org\/10.1007\/s00701-016-2762-z.","journal-title":"Acta Neurochir (Wien)."},{"issue":"4","key":"5604_CR39","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.surneu.2009.04.012","volume":"72","author":"J D'Haens","year":"2009","unstructured":"D'Haens J, Van Rompaey K, Stadnik T, Haentjens P, Poppe K, Velkeniers B. Fully endoscopic transsphenoidal surgery for functioning pituitary adenomas: a retrospective comparison with traditional transsphenoidal microsurgery in the same institution. Surg Neurol. 2009;72(4):336\u201340. https:\/\/doi.org\/10.1016\/j.surneu.2009.04.012.","journal-title":"Surg Neurol."},{"issue":"1","key":"5604_CR40","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11102-009-0195-x","volume":"13","author":"JA Gondim","year":"2010","unstructured":"Gondim JA, Schops M, de Almeida JP, de Albuquerque LA, Gomes E, Ferraz T, et al. Endoscopic endonasal transsphenoidal surgery: surgical results of 228 pituitary adenomas treated in a pituitary center. Pituitary. 2010;13(1):68\u201377. https:\/\/doi.org\/10.1007\/s11102-009-0195-x.","journal-title":"Pituitary."},{"issue":"4","key":"5604_CR41","doi-asserted-by":"publisher","DOI":"10.3171\/2011.1.FOCUS10317","volume":"30","author":"CP Hofstetter","year":"2011","unstructured":"Hofstetter CP, Shin BJ, Mubita L, Huang C, Anand VK, Boockvar JA, et al. Endoscopic endonasal transsphenoidal surgery for functional pituitary adenomas. Neurosurg Focus. 2011;30(4):E10. https:\/\/doi.org\/10.3171\/2011.1.FOCUS10317.","journal-title":"Neurosurg Focus."},{"issue":"3","key":"5604_CR42","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3325\/cmj.2012.53.224","volume":"53","author":"A Maric","year":"2012","unstructured":"Maric A, Kruljac I, Cerina V, Pecina HI, Sulentic P, Vrkljan M. Endocrinological outcomes of pure endoscopic transsphenoidal surgery: a Croatian Referral Pituitary Center experience. Croat Med J. 2012;53(3):224\u201333. https:\/\/doi.org\/10.3325\/cmj.2012.53.224.","journal-title":"Croat Med J"},{"issue":"11","key":"5604_CR43","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.jocn.2015.06.001","volume":"22","author":"TR Smith","year":"2015","unstructured":"Smith TR, Hulou MM, Huang KT, Gokoglu A, Cote DJ, Woodmansee WW, et al. Current indications for the surgical treatment of prolactinomas. J Clin Neurosci. 2015;22(11):1785\u201391. https:\/\/doi.org\/10.1016\/j.jocn.2015.06.001.","journal-title":"J Clin Neurosci."},{"issue":"7","key":"5604_CR44","doi-asserted-by":"publisher","first-page":"501","DOI":"10.2176\/nmc.53.501","volume":"53","author":"T Tanei","year":"2013","unstructured":"Tanei T, Nagatani T, Nakahara N, Watanabe T, Nishihata T, Nielsen ML, et al. Use of high-field intraoperative magnetic resonance imaging during endoscopic transsphenoidal surgery for functioning pituitary microadenomas and small adenomas located in the intrasellar region. Neurol Med Chir (Tokyo). 2013;53(7):501\u201310. https:\/\/doi.org\/10.2176\/nmc.53.501.","journal-title":"Neurol Med Chir (Tokyo)."},{"issue":"1","key":"5604_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2176\/nmc.49.1","volume":"49","author":"S Yano","year":"2009","unstructured":"Yano S, Kawano T, Kudo M, Makino K, Nakamura H, Kai Y, et al. Endoscopic endonasal transsphenoidal approach through the bilateral nostrils for pituitary adenomas. Neurol Med Chir (Tokyo). 2009;49(1):1\u20137. https:\/\/doi.org\/10.2176\/nmc.49.1.","journal-title":"Neurol Med Chir (Tokyo)."},{"issue":"3-4","key":"5604_CR46","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1159\/000095534","volume":"83","author":"G Frank","year":"2006","unstructured":"Frank G, Pasquini E, Farneti G, Mazzatenta D, Sciarretta V, Grasso V, et al. The endoscopic versus the traditional approach in pituitary surgery. Neuroendocrinology. 2006;83(3-4):240\u20138. https:\/\/doi.org\/10.1159\/000095534.","journal-title":"Neuroendocrinology."},{"key":"5604_CR47","doi-asserted-by":"publisher","unstructured":"Anglemyer A, Horvath HT, Bero L. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. Cochrane Database Syst Rev. 2014;4(4). https:\/\/doi.org\/10.1002\/14651858.MR000034.pub2.","DOI":"10.1002\/14651858.MR000034.pub2"},{"key":"5604_CR48","doi-asserted-by":"publisher","first-page":"i493","DOI":"10.1136\/bmj.i493","volume":"352","author":"LG Hemkens","year":"2016","unstructured":"Hemkens LG, Contopoulos-Ioannidis DG, Ioannidis JPA. Agreement of treatment effects for mortality from routinely collected data and subsequent randomized trials: meta-epidemiological survey. BMJ. 2016;352:i493. https:\/\/doi.org\/10.1136\/bmj.i493.","journal-title":"BMJ."},{"issue":"5","key":"5604_CR49","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1007\/s11606-020-05713-5","volume":"35","author":"SP Forbes","year":"2020","unstructured":"Forbes SP, Dahabreh IJ. Benchmarking observational analyses against randomized trials: a review of studies assessing propensity score methods. J Gen Intern Med. 2020;35(5):1396\u2013404. https:\/\/doi.org\/10.1007\/s11606-020-05713-5.","journal-title":"J Gen Intern Med."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05604-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-021-05604-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05604-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T19:13:48Z","timestamp":1632597228000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-021-05604-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,25]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5604"],"URL":"https:\/\/doi.org\/10.1186\/s13063-021-05604-y","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,25]]},"assertion":[{"value":"11 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval has been obtained from the Medical Ethics Review Committee Leiden-The Hague-Delft (P18.219, 12 March 2019). Written informed consent to participate will be obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"653"}}